Higher Dose of This Antibiotic Can Help In Tuberculosis Recovery: Study
A higher dose of rifampicin -- a bactericidal antibiotic used primarily to treat tuberculosis (TB) -- may be safe, and its use can potentially lead to recurrence-free survival in patients with pulmonary TB, according to a recent study by the Indian Council of Medical Research (ICMR).
TB is curable but still remains the most common cause of death due to infectious diseases, with an estimated 1.3 million deaths globally in 2022. Rifamycins are a crucial drug group in the anti-TB regimen, which sterilise the lesions and aid in recurrence-free cure.
Currently, rifampicin is administered at 10 mg/kg for six months to all patients with pulmonary TB.
The team reviewed the available evidence from published clinical trials to determine whether higher doses of rifampicin (more than 15 mg/kg) are more efficacious and safer.
"Compared to standard dose, higher doses of rifampicin were found to lead to early sputum conversion in eight weeks and thus faster TB bacteria clearance," said corresponding author Dr Leeberk Raja Inbaraj, Department of Clinical Research, ICMR- National Institute for Research in Tuberculosis, Chennai.
Early sputum conversion is a valuable tool widely used as a surrogate marker for treatment response and those who are at risk for relapse in pulmonary TB.
"The ability of high-dose rifampicin to achieve early sputum conversion and eliminate the persistent bacteria that cause relapse could potentially lead to recurrence-free survival. Early bacterial clearance is also of public health importance as this could potentially reduce disease transmission in the community," the researchers said.
Notably, the study showed 20-30mg/kg rifampicin as the best balance.
"This dose range showed better sputum conversion without a significant increase in serious side effects and may be considered in TB treatment," revealed the study, published in the Indian Journal of Medical Research (IJMR).
On the other hand, doses above 30 mg/kg, although beneficial, came with severe side effects such as serious liver damage (hepatotoxicity) and adverse drug reactions (ADR), leading to treatment discontinuation.
The study showed no reduction in death or treatment failure in people with more than 15 mg/kg doses of rifampicin.
"High doses did not reduce mortality or treatment failure at 6 months compared to standard treatment," the team said.
"This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence," they added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
6 hours ago
- Fashion Value Chain
Fortis Hospitals Mumbai Launches Citywide Campaign for Brain Health Awareness on World Brain Day
On the occasion of World Brain Day 2025, Fortis Hospitals Mumbai launched a unique citywide awareness campaign titled 'Helmet Pehna Kya', in an attempt to spark public dialogue around the importance of brain health and proactive care. The campaign, saw more than fifty volunteers walk the streets of Mumbai wearing helmets in unexpected places. Fortis Mumbais Helmet Pehna Kya sqad all set to engage Mumbaikars on World Brain Day 2025 Volunteers wearing helmets attracted attention and struck up conversations everywhere from local trains and flower markets to office parks and roadside food stands, leading Mumbaikars to wonder, 'Why are they wearing the helmet here'The answer To emphasize a crucial point: your brain should be protected every day, not only in the event of an accident. Fortis Hospitals Mumbai questioned common belief that brain safety is solely related to accident-related trauma by introducing a symbol of physical protection (the helmet) in routine, low or no-risk situations. Instead, the campaign reframed helmets as a symbol of routine checkups, mental wellness, early detection, and lifestyle modification. The initiative aims to remind people that brain health is a daily priority rather than an emergency, this innovative activation not only attracted Mumbaikars attention but also struck the relevant conversations. This initiative couldn't be timed better. Across India, neurological disorders are becoming an everyday reality for more and more families. Over the past three decades, cases of conditions like Stroke, Epilepsy, Migraine, and Dementia have more than doubled. Today, these account for almost 10% of the nation's overall disease burden; Stroke alone took the lives of nearly 7 lakh people in 2019. What's alarming is that stressors we live with daily: high blood pressure, poor diet choices, rising pollution levels, and chronic mental strain are the triggers. A comprehensive study led by the India State-Level Disease Burden Initiative-supported by ICMR, PHFI, IHME, and the Ministry of Health-highlighted these trends and published the findings in The Lancet Global Health. It is wake-up call, our brain health is far more fragile than we realise. That's what makes the Fortis Mumbai campaign so meaningful. By turning helmet into a powerful symbol, and carries a message that's hard to miss: protecting your brain is not just about reacting to emergencies; it's about living more mindfully, every single day. Talking about the initiative, Dr S Narayani, Business Head – Fortis Hospitals, Maharashtra, said, 'At Fortis, our mission goes beyond treating illness, we aim to prevent it through education and awareness. The helmet is a powerful choice for the campaign as it reminds us that just as we protect our head from injury on the roads, we must also protect our brain through awareness, timely action, and healthy choices. For us preventative healthcare is the foundation of a healthy society and through this campaign, we hope to engage the community, and empower them to take proactive steps towards better brain health.' As part of World Brain Day, Fortis Hospitals in Mumbai brought brain health awareness to the forefront with a unique, people-first approach. At all four units-Mulund, Kalyan, Vashi, and Mahim-Patient Care Services staff wore helmets within hospital premises, sparking heartfelt conversations with patients and their families about the importance of brain health. Community sessions hosted at open spaces helped Neurologists share insights on recognizing early warning signs, and stressed the value of timely care. The initiative extended to notable locations across Mumbai, as reactions and real-time moments were shared across Fortis Mumbai's social media pages, helping the message of brain health reach the community at large. 'When it comes to brain health, lifestyle plays a very important role and should not be overlooked. One particular acronym that tell my patients to lookout for is termed SHAAADOWSSS, which stands for Smoking, Hypertension, Age over 60 years, Alcohol Abuse, Atrial fibrillation, Diabetes, Obesity, Wellspring (family history), Stress, Sedentary Lifestyle and Sleep Disorders. True to its name, these conditions follow you around like a shadow and if left unmanaged they significantly increase your risk of developing issues like Stroke. The good news is simple, conscious changes in your daily routine can drastically lower that risk and protect your brain for the long run,' said Dr Ashok Hande, Director – NeuroSurgery, Fortis Hiranandani Hospital, Vashi, while talking about the role lifestyle awareness plays in brain health preservation. Dr Sreelakshmi N. Consultant-Neurology, S.L. Raheja Hospital, Mahim, said, 'Everything you experience flows from the brain. Yet, your brain remains the body's most sensitive organs. Issues like Stroke can appear suddenly, while conditions such as Dementia may develop gradually and quietly. That's why paying attention to even subtle changes matters. Don't ignore the signs your body may be giving you. Acting early can change outcomes.' Highlighting the role family history, Dr Gurneet Singh Sawhney, Director-Stereotaxy and Functional Neurosciences, Fortis Hospital, Mulund said, 'Family history plays a crucial role when managing disease burden. If someone in the patient's family has had ailments like Dementia, Stroke etc. then one's chances of developing neurological complications may be higher. That makes it even more critical to be aware of the warning signs, get regular health check-ups, and adopt a healthy lifestyle to reduce your risk.' DrRushabh Chheda, Consultant, Neurosurgery and Stroke Intervention Specialist, Fortis Hospital Kalyan, said, 'Brain health is too important to take chances with. Any warning sign you observe should be taken as a medical emergency, not be considered a wait-and-watch situation. There is a common saying in Neurology which says – time is brain – thus the quicker you act, the more brain function can be saved and every minute counts when it comes to protecting your brain and your life, so act fast to preserve what matters most.' The message is clear: it's time for Mumbai to act decisively with stronger strategies for prevention, better awareness, and more accessible neurological care-before this silent epidemic grows louder. About Fortis Healthcare Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organizations in the country with 27 healthcare facilities, ~4,750 operational beds (including O&M facilities), and over 400 diagnostics centers (including JVs). The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with a global major and parent company – IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs over 23,000 people (including Agilus Diagnostics Limited) who share its vision of becoming the world's most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.
Time of India
21 hours ago
- Time of India
Gadkari inaugurates daycare facility for infectious diseases at city hospital
1 2 3 4 Nagpur: Ishra Health, formerly known as Tayade's Clinic, has introduced a daycare facility for infectious disease treatment at its newly upgraded facility in Nagpur. The facility was inaugurated by Union minister Nitin Gadkari recently. The centre is equipped with modern amenities, and well-trained staff. Dr Ashwini Tayade heads the department of infectious diseases. Tayade specialises in the diagnosis and treatment of complex infectious diseases including HIV, Tuberculosis (TB), and infection-related cancers. Ishra Health also offers advanced cancer care services under the leadership of Dr Ramakant Tayade, onco-surgeon with a career spanning over two decades. Dr Ramakant Tayade specialises in the surgical treatment of breast cancer, oral, head and neck cancers, thyroid cancer, gastrointestinal and colorectal cancers, esophagus and pancreatico-biliary cancers, and gynaecological malignancies.
New Indian Express
a day ago
- New Indian Express
AdFalciVax: India's shot at stopping malaria on its tracks
India will soon have an advanced vaccine against malaria. In a major scientific breakthrough, the Indian Council of Medical Research (ICMR) has developed an innovative recombinant, chimeric multi-stage malaria vaccine that could transform malaria prevention and control efforts in India and globally. Named AdFalciVax, the vaccine has been developed to offer both protection against Plasmodium falciparum infection in humans and interruption of community transmission, unlike the existing two vaccines that can partially prevent infection in humans but cannot stop transmission in the community. The novel vaccine developed by Regional Medical Research Centre (RMRC), Bhubaneswar, one of the constituent institutes of ICMR, is now ready for technology transfer to manufacturers or organisations for production, clinical trials and its commercialisation. Preliminary trials on animal models have been highly successful. The pre-clinical validation of the vaccine has been conducted in collaboration with National Institute of Malaria Research (NIMR), another constituent institute of ICMR, and National Institute of Immunology (NII), New Delhi, an autonomous research institute of the Department of Biotechnology, Government of India. A dual-stage game changer Unlike the currently available WHO-recommended vaccines - RTS, S/AS01 (Mosquirix), and R21/Matrix-M which have shown efficacies ranging between 33% and 67%, AdFalciVax promises dual-stage protection. It will not only shield people from contracting the deadliest strain of malaria but also prevent its spread within communities, considered an essential factor in breaking the chain of transmission. Dr Susheel Singh, scientist-D at RMRC, said AdFalciVax deploys a full-length PfCSP (circumsporozoite protein), a key surface antigen of P falciparum, for broader immune protection. It also incorporates a novel fusion of Pfs230 and Pfs48/45 proteins to induce potent transmission-blocking antibodies. 'The new vaccine can prevent human infection and interrupts transmission in the community, thereby tackling two critical developmental bottlenecks in the malaria parasite's life cycle,' Dr Singh said. The RMRC researchers said the vaccine has been developed using advanced protein engineering techniques and it leverages Lactococcus lactis, a safe bacterial host system, for antigen production. Additional director general of ICMR and director of RMRC Dr Sanghamitra Pati said preclinical trials conducted on mice showed robust and long-lasting immunity, even when exposed to 10,000 dual-transgenic Plasmodium berghei parasites engineered to express P falciparum antigens. 'The immune protection lasted over four months post-booster dose, which translates to more than a decade of protection in humans. The vaccine was administered with safe alum-based adjuvants and showed no adverse reactions,' said Dr Pati. Senior scientist Dr Subhash Singh was also a key contributor to the development of the vaccine. High stability at low cost The uniqueness of AdFalciVax over existing vaccines is its pharmaceutical stability. The formulation remains potent for over nine months at room temperature, doing away with the need for expensive cold chain logistics, which continue to be a long-standing challenge in vaccine distribution, especially in remote and under-resourced regions. The vaccine is also highly cost-effective, with an estimated production cost of just `20 per dose. The current vaccines are priced between `250 and `830 per dose. The affordability of the newly developed vaccine could make mass immunisation programmes significantly more viable. ICMR has now invited expressions of interest from eligible firms and manufacturers for technology transfer and commercial-scale production. The vaccine is expected to go for clinical trial stages soon and potentially be rolled out for public use in the next few years. However, the efficacy during the clinical trials will be the key.
